Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinopathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    376 result(s) found for: Retinopathy. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-003865-20 Sponsor Protocol Number: 21618 Start Date*: 2021-03-02
    Sponsor Name:Bayer AG
    Full Title: A clinical trial collecting Data from routine ophthalmological examinations of patients who were randomized to either finerenone or placebo in the two Bayer-sponsored Phase 3 clinical trials FIDELI...
    Medical condition: Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005315-10 Sponsor Protocol Number: 2006-011 Start Date*: 2006-09-05
    Sponsor Name:OSPEDALE SACRO CUORE-DON CALABRIA
    Full Title: Evaluation of safety and efficacy on visual acuity outcome of intravitreal somministration of Bevacizumab in patients with diabetic retinopathy
    Medical condition: Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000250-19 Sponsor Protocol Number: CADODIAME Start Date*: 2017-06-13
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR)
    Full Title: Effect of calcium dobesilate in early stages of diabetic retinopathy
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003955-23 Sponsor Protocol Number: DR2 Start Date*: 2016-04-15
    Sponsor Name:Dept. of Ophthalmology, Rigshospitalet – Glostrup
    Full Title: Diabetic retinopathy: Effects of melatonin treatment on visual functions and circadian rhythm.
    Medical condition: Diabetic Retinopathy and Sleep disorder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002333-15 Sponsor Protocol Number: 20739 Start Date*: 2021-01-15
    Sponsor Name:Bayer AG
    Full Title: A Phase 2 randomized, placebo-controlled, double-masked proof-of concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-p...
    Medical condition: - Non-proliferative diabetic retinopathy: early stage of a medical condition in which damage occurs to the retina due to diabetes mellitus (DM) - DM is characterized by too much sugar in the blood
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10054109 Non-proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Completed) CZ (Completed) PT (Completed) NL (Completed) DK (Completed) HU (Prematurely Ended) IT (Prematurely Ended) SK (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-005032-33 Sponsor Protocol Number: 70242 Start Date*: 2009-01-22
    Sponsor Name:Gedeon Richter Plc.
    Full Title: Single center, exploratoric, double-blind, placebo controlled study to investigate the efficacy and tolerability of vinpocetine in patients with non-proliferative diabetic retinopathy
    Medical condition: Patients with type 2 diabetes mellitus with mild or moderate or severe non-proliferative diabetic retinopathy (NPDR).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054109 Non-proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-009909-25 Sponsor Protocol Number: KTvsMM1/09 Start Date*: 2009-05-05
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt
    Full Title: Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial
    Medical condition: Medical condition: moderate to severe non-proliferative retinopathy with diabetic cystoid macular edema.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002656-24 Sponsor Protocol Number: CTSULENS1 Start Date*: 2018-01-23
    Sponsor Name:University of Oxford (Clinical Trials and Research Governance))
    Full Title: A randomised placebo-controlled clinical trial of fenofibrate to prevent progression of non-proliferative retinopathy in diabetes
    Medical condition: Diabetic retinopathy and diabetic maculopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    20.0 10015919 - Eye disorders 10025425 Maculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003297-81 Sponsor Protocol Number: PDRPOZU1 Start Date*: 2011-09-12
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized study on intravitreal Ozurdex for preventing recurrent vitreous hemorrhage following pars plana vitrectomy for proliferative diabetic retinopathy
    Medical condition: Proliferative diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002639-14 Sponsor Protocol Number: VGFTe-OD-1411 Start Date*: 2016-12-29
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
    Medical condition: NonProliferative Diabetic Retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001764-29 Sponsor Protocol Number: VGFTe-ROP-1920 Start Date*: 2020-12-01
    Sponsor Name:Regeneron Pharmaceuticals. Inc.
    Full Title: Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) BG (Completed) BE (Completed) PT (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002611-99 Sponsor Protocol Number: 20090 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer AG
    Full Title: Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy ...
    Medical condition: Retinopathy of prematurity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) NL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) SK (Completed) AT (Completed) BG (Completed) PL (Completed) ES (Completed) HU (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002415-15 Sponsor Protocol Number: TG-MV-015 Start Date*: 2016-02-17
    Sponsor Name:ThromboGenics NV
    Full Title: A PHASE 2, RANDOMISED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRIPLASMIN IN INDUCING TOTAL POSTERIOR VITREOUS DETACHMENT (PVD) IN SUBJECTS WITH N...
    Medical condition: Moderately severe to very severe non-proliferative diabetic retinopathy (NPDR)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10054109 Non-proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) CZ (Completed) BE (Completed) HU (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012609-20 Sponsor Protocol Number: 343/09 Start Date*: 2009-09-08
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: INTRAVITREAL BEVACIZUMAB INJECTION VS. CONVENTIONAL LASER SURGERY FOR VISION-THREATENING RETINOPATHY OF PREMATURITY.
    Medical condition: AP-ROP
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038933 Retinopathy of prematurity LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004048-36 Sponsor Protocol Number: CRFB002H2301E1 Start Date*: 2016-04-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy o...
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) IT (Completed) BE (Completed) LT (Completed) CZ (Completed) DE (Completed) AT (Completed) SE (Completed) GR (Completed) DK (Completed) FR (Completed) HR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001351-23 Sponsor Protocol Number: EGT022-01 Start Date*: 2017-08-15
    Sponsor Name:EyeGene, Inc
    Full Title: A phase IIa, randomized, placebo-controlled, double-blind, parallel study to investigate the efficacy of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabet...
    Medical condition: diabetic retinopathy patients having early diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001678-25 Sponsor Protocol Number: 138/06 Start Date*: 2006-02-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for vascular retinopathy a interventional study.
    Medical condition: vascular retinopathy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038923 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002067-10 Sponsor Protocol Number: BP41321 Start Date*: 2020-07-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-masked, 48-week parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with Diabetes Mellitus Type 1 or Type 2 ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005601-22 Sponsor Protocol Number: poc1doxy Start Date*: 2008-03-27
    Sponsor Name:
    Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001200-38 Sponsor Protocol Number: 4C-2011-02 Start Date*: 2012-09-07
    Sponsor Name:BCN Peptides S.A.
    Full Title: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomized controlled trial to assess the efficacy of neuroprotective dru...
    Medical condition: Prevention of neurodegeneration which occurs in Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    15.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 18:32:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA